approval
saveLEQVIO (INCLISIRAN SODIUM) — FDA approval
community read0 votes
Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 7
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalFeb 12, 2026 · 241d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalFeb 12, 2026 · 241d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalJul 31, 2025 · 437d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalJun 6, 2024 · 857d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalJul 7, 2023 · 1192d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalFeb 17, 2023 · 1332d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalDec 22, 2021 · 1754d ago
same company · ±60 days · 4
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalMay 27, 2022
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMay 27, 2022
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalJun 22, 2022
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalJun 22, 2022
comments(0)
5-min edit window · permanent after that